Archives
-
Human iPSC Intestinal Organoids for PK Studies
2026-09-17
Saito and colleagues established a direct three-dimensional culture workflow for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids can be propagated, cryopreserved, and converted into two-dimensional intestinal epithelial cultures with enterocyte-associated metabolic and transporter activities, offering a more human-relevant platform for oral drug pharmacokinetic studies.
-
MG-132 for Reliable Cell Death Assays
2026-09-17
This scenario-driven guide explains how MG-132 (SKU A2585) can improve experimental planning for viability, apoptosis, cell-cycle, and oxidative-stress assays. It connects formulation, storage, dose selection, and ferroptosis-related interpretation to practical laboratory decisions.
-
BRCAness and Olaparib Sensitivity in Mesothelioma
2026-09-16
Borchert et al. combined drug-response experiments with homologous recombination repair gene-expression profiling to investigate why malignant pleural mesothelioma may respond to PARP inhibition. Their data link BAP1-associated BRCAness with enhanced olaparib activity, particularly alongside cisplatin, while identifying a clinically relevant expression pattern and candidate prognostic markers.
-
Chlorpromazine: A Rigorous Assay Design Guide
2026-09-16
Chlorpromazine can serve as more than a dopamine-pathway probe: it can help researchers design and interpret pharmacological assays across neurobiology and nanomedicine. This guide connects chlorpromazine hydrochloride research with cell-specific nanoparticle uptake findings while emphasizing controls, assay boundaries, and reproducibility.
-
Aminopeptidase Selectivity of ACE Inhibitors
2026-09-15
This 1992 study re-evaluated how bestatin and several metallopeptidase inhibitors affect aminopeptidases N, A, and W. Its central contribution was to distinguish broad aminopeptidase inhibition from comparatively selective ACE-inhibitor activity, while identifying sulfhydryl ACE inhibitors as a possible source of AP-W-related off-target effects.
-
From Reporter Signal to Translational Confidence
2026-09-15
A thought-leadership framework for using Firefly Luciferase mRNA as a mechanistically informed control in delivery studies, from assay validation to regenerative-medicine translation.
-
Peptidisc-Assisted Nanobody Clustering: Study Insights
2026-09-14
The reference preprint introduces peptidisc-assisted hydrophobic clustering as a way to assemble nanobodies into soluble multimeric, bispecific, and autofluorescent proteins. Its results suggest that membrane-mimetic stabilization can translate nanobody multivalency into stronger apparent binding while avoiding conventional tandem-linker or scaffold-fusion designs.
-
Forskolin and the Next Generation of Organoid Models
2026-09-14
Forskolin is more than a routine cAMP reagent: as a direct adenylate cyclase activator, it can become a controllable perturbation for organoid engineering, stem-cell validation, and translational disease modeling. This article connects its mechanism with pancreatic ductal organoid research while defining practical safeguards for moving from pathway activity to meaningful biological insight.
-
Angiotensin I Workflow for ACE Assays
2026-09-13
Use Angiotensin I as a defined substrate to separate renin–angiotensin system activity from downstream receptor effects. This practical workflow combines ACE-conversion controls, peptide-handling guidance, spectral quality lessons, and applications in cardiovascular disease mechanisms, antihypertensive drug screening, and neuroendocrine models.
-
Bufuralol Hydrochloride in Human Organoid PK
2026-09-12
Bufuralol hydrochloride is a non-selective β-adrenergic receptor antagonist whose partial agonist behavior makes exposure and model context central to interpretation. This article connects its cardiovascular pharmacology with human iPSC-derived intestinal organoids to develop a more rigorous framework for pharmacokinetic and β-adrenergic modulation studies.
-
Clarithromycin CYP3A Inhibition: Bench Workflow
2026-09-11
Use Clarithromycin as a controlled CYP3A inhibitor challenge for drug-drug interaction research, statin metabolism interaction assays, and translational pharmacokinetic studies. This workflow emphasizes solvent control, matrix selection, orthogonal controls, and the important contrast between CYP3A-dependent metabolism and dabigatran pathways that do not rely on cytochrome P450.
-
VE-822: From ATR Biology to Translational PDAC
2026-09-11
A thought-leadership guide to using VE-822 as an ATR inhibitor in pancreatic ductal adenocarcinoma research, connecting DNA damage response inhibition, radiosensitization, 2D-to-3D validation, and patient-specific translational strategy.
-
PEGylated Iron Oxide Nanoparticles in the Liver
2026-09-10
This ACS Nano study separates the effects of iron oxide nanoparticle size and PEG chain length on hepatic distribution by combining 99mTc-SPECT/CT with primary liver-cell uptake assays. Its results show that hepatocytes and hepatic stellate cells can contribute substantially to uptake, while an intermediate PEG length may reduce hepatic accumulation more effectively than the longest coating.
-
Digoxin: A Disease-Aware Assay Strategy
2026-09-10
Digoxin research is strengthened by connecting Na+/K+ ATPase pump inhibition with disease-state-aware assay design. This guide integrates cardiac, antiviral, and pharmacokinetic reasoning to improve interpretation of exposure, cellular response, and translational relevance.
-
Bufuralol hydrochloride: Organoid PK Workflows
2026-09-09
Learn how Bufuralol hydrochloride can connect human iPSC-derived intestinal organoid pharmacokinetics with β-adrenergic modulation studies. This practical guide covers preparation, exposure design, assay controls, troubleshooting, and translational interpretation for cardiovascular pharmacology research.